AlgiPharma Phase I clinical trial shows excellent safety and tolerability data for respiratory diseases

OligoG CF-5/20 was well tolerated when administered by inhalation to 28 healthy subjects. All adverse events monitored were mild and transient. No serious adverse events, no deaths, no discontinuations.

Read more

For more information contact:
Yngvar P. Berg, CEO;
Astrid Hilde Myrset, Clinical Director;

January 2010

AlgiPharma granted permission to start Phase I trials in Cystic Fibrosis

A clinical phase I for AlgiPharma’s prospective medicine for Cystic Fibrosis (respiratory diseases), Oligo-G CF-5/20, was approved by the Medicines and Healthcare Product Regulatory Agency, MRHA, and is initiated at SIMBEC (UK) and scheduled to be concluded before the end of the year. Results are set to be reported in the first quarter of 2010.

For more information contact:
Yngvar P. Berg, CEO, +47 90044903;
Astrid Hilde Myrset, Clinical Director, +47 93026094;

September 2009